Monopar Therapeutics MNPR Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Monopar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Monopar Therapeutics’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monopar Therapeutics's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monopar Therapeutics's financing cash flow?
- Monopar Therapeutics (MNPR) reported financing cash flow of -$200.2K in Q1 2026.
- How has Monopar Therapeutics's financing cash flow changed year-over-year?
- Monopar Therapeutics's financing cash flow decreased by 73.1% year-over-year, from -$115.68K to -$200.2K.
- What is the long-term trend for Monopar Therapeutics's financing cash flow?
- Over 2 years (2022 to 2025), Monopar Therapeutics's financing cash flow has grown at a 5189.0% compound annual growth rate (CAGR), from $32.87K to $91.96M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.